Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for cystic fibrosis (CF). Its primary products include SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, which target specific genetic mutations in the CFTR gene. Revenue primarily comes from sales of these CF therapies, which constitute approximately 90% of total revenue, while the remaining 10% comes from collaborations and pipeline products in various stages of clinical trials. Factors supporting the company's endurance include its specialized focus on a niche market with high unmet medical needs and a strong pipeline of potential therapies. However, competition and the risk of regulatory changes could limit its long-term sustainability.
—
Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for cystic fibrosis (CF). Its primary products include SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, which target specific genetic mutations in the CFTR gene. Revenue primarily comes from sales of these CF therapies, which constitute approximately 90% of total revenue, while the remaining 10% comes from collaborations and pipeline products in various stages of clinical trials. Factors supporting the company's endurance include its specialized focus on a niche market with high unmet medical needs and a strong pipeline of potential therapies. However, competition and the risk of regulatory changes could limit its long-term sustainability.
—
Daily adjusted close
Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for cystic fibrosis (CF). Its primary products include SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, which target specific genetic mutations in the CFTR gene. Revenue primarily comes from sales of these CF therapies, which constitute approximately 90% of total revenue, while the remaining 10% comes from collaborations and pipeline products in various stages of clinical trials. Factors supporting the company's endurance include its specialized focus on a niche market with high unmet medical needs and a strong pipeline of potential therapies. However, competition and the risk of regulatory changes could limit its long-term sustainability.